Roxithromycin

Roxithromycin

록시트로마이신

항생물질제제

80214-83-1

20050831-9-A-2-02(12)

Zhejiang Zhenyuan Pharmaceutical Co. Ltd.

EP/In-house

(3R,4S,5S,6R,7R,9R,11S,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-10-(2,4,7-trioxa-1-azaoctan-1-ylidene)-1-oxacyclotetradecan-2-one

(9E)-erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime)

Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to erythromycin, azithromycin, or clarithromycin . It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila . Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections.

If you need more information, please contact us.